术前NLR、PLR在非小细胞肺癌患者预后中的价值

目的:评估术前中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)、血小板/淋巴细胞比值(platelet to lymphocyte ratio,PLR)在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后中的价值。方法:回顾性分析2012年1月至2014年4月在四川省肿瘤医院行根治性手术治疗的280例NSCLC患者的临床病理资料,根据受试者工作特征曲线(receiver operating characteristic curve,ROC)确定NLR、PLR的临界值,分析NLR、PLR与患者预后的相关性。结果:选取NLR=3.25和PLR=122作为临界值。单因素分析显示TNM分期、T分期、N分期与无病生存期(disease-free survival,DFS)相关,P值分别为0.001、0.007、<0.001;年龄、TNM分期、T分期、N分期、PLR与总生存期(overall survival,OS)相关,P值分别为0.006、<0.001、0.035、<0.001、<0.001。多因素分析显示TNM分期(HR:1.627,95%CI:1.030～2.568,P=0.037)是影响DFS的独立危险因素。年龄(HR:1.785,95%CI:1.216～2.622,P=0.003)、TNM分期(HR:2.094,95%CI:1.231～3.560,P=0.006)、PLR(HR:1.833,95%CI:1.257～2.674,P=0.002)是影响OS的独立危险因素。结论:PLR或可作为评估经根治性手术治疗NSCLC患者预后的参考指标。

Value of Preoperative NLR and PLR in the Prognosis of Non-small Cell Lung Cancer

Diao Peng;Huang Qing;Li Changlin;Peng Qian;Xie Tianpeng;Tan Yan(Department of Radiotherapy,Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041 , Sichuan, China;Department of Thoracic Surgery , Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041 , Sichuan, China;Department of Oncology,Chengdu First Peoples’Hospital, Chengdu 610016, Sichuan, China)